文献速递腹部技术与安全USMR

胆总管结石的胆管直径与胆红素水平时间变化

Temporal Changes in Biliary Duct Diameter with Correlated Bilirubin Levels in Confirmed Choledocholithiasis: A Prospective 3 Time-Point Observational Ultrasound Study.
PubMed 文献 · J Ultrasound Med · 2026-09-17

本前瞻性单中心研究纳入46例急性右上腹痛、超声证实胆囊结石且MRCP/ERCP证实胆总管结石患者,在<24、24-48、48-72小时三个时间点测量CBD/IHD并检测血清总/直接胆红素。结果显示CBD扩张率从34.8%升至95.7%,平均CBD直径由5.7±2.3 mm增至12.1±2.5 mm。连续超声评估CBD直径联合胆红素变化可明显提高胆总管结石诊断敏感度。

要点

  • 急诊超声对胆总管结石可能假阴性,CBD可表现正常
  • 48-72小时后复查CBD直径及胆红素可提高诊断率
  • CBD直径联合总/直接胆红素动态变化是实用诊断线索

核心结论

  • 胆总管结石患者急诊超声可能呈假阴性,连续超声评估CBD直径尤其联合胆红素变化可显著提高诊断敏感度。
  • 在3天内重复超声和实验室检查有助于胆总管结石的恰当处理。

研究设计与样本

  • 单中心前瞻性研究,纳入46例急性右上腹痛、超声证实胆囊结石且MRCP/ERCP证实胆总管结石患者。
  • 在<24小时、24-48小时、48-72小时三个时间点行CBD/IHD超声测量及血清总/直接胆红素检测。
  • 统计学显著性设为P<.01。

关键影像表现/征象

  • CBD扩张率从t1为34.8%,t2为69.6%,t3为95.7%。
  • 平均CBD直径从5.7±2.3 mm增加至8.2±2.7 mm和12.1±2.5 mm。
  • IHD扩张率从2.1%增加至19.6%和78.3%。

诊断标准与关键数值

  • CBD扩张诊断胆总管结石的敏感度在t1为34.8%,t2为69.6%,t3为95.7%。
  • CBD扩张联合总胆红素诊断敏感度在t1为56.5%,t2为87%,t3为95.7%。
  • CBD扩张联合直接胆红素诊断敏感度在t1为78.3%,t2为91.3%,t3为95.7%。
  • 总/直接胆红素水平在各时间点间持续升高,t1至t3增加最明显,P值分别为.0003和.0006。

临床应用与阅片要点

  • 对疑似胆总管结石患者,首次超声CBD未扩张不能排除诊断。
  • 建议在症状出现后3天内复查超声,动态观察CBD和IHD直径变化。
  • 将CBD测量与总/直接胆红素趋势结合判断,比单一指标更可靠。

局限性

  • 单中心研究,样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Choledocholithiasis often coexists with symptomatic cholelithiasis, and early detection is crucial to prevent complications. In these patients, the common bile duct (CBD) may appear non-dilated on ultrasonography (US). Studies on the temporal evolution of CBD measurements and corresponding bilirubin levels are currently lacking. Herein, we aim to evaluate the temporal evolution and correlation of CBD/intrahepatic duct (IHD) dilatation with serum bilirubin levels in patients with choledocholithiasis.

METHODS: In this single-center prospective study, we included 46 patients with acute right upper quadrant pain, sonographically confirmed cholelithiasis and MRCP/ERCP confirmed choledocholithiasis. CBD/IHD US measurements and serum total/direct bilirubin levels were obtained at <24 (t1), 24-48 (t2), and 48-72 hours (t3). Serial CBD/IHD diameters were correlated with bilirubin concentrations. Statistical significance was set at p < .01.

RESULTS: Prevalence of CBD dilatation increased from 34.8% at t1 to 69.6% at t2 and 95.7% at t3. Mean CBD diameters increased from 5.7 ± 2.3 mm to 8.2 ± 2.7 mm and 12.1 ± 2.5 mm (p < .0001). IHD dilatation incidence increased from 2.1 to 19.6% and 78.3%. Total/direct bilirubin levels progressed between all time-points, with the greatest increase between t1 and t3 (p = .0003/p = .0006). Sensitivity of CBD dilatation for diagnosing choledocholithiasis was 34.8, 69.6, and 95.7% increasing to 56.5%/78.3%, 87%/91.3% and 95.7%/95.7% when combined with total/direct bilirubin across t1, t2, and t3, respectively.

CONCLUSIONS: In patients with choledocholithiasis, emergency US may be false-negative. Serial US assessment of CBD diameter, particularly when combined with bilirubin trends, substantially improves diagnostic sensitivity. Repeat US and laboratory investigations within up to 3 days are supported for appropriate patient management.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Giannaki, Klontzas, Perysinakis, et al. Temporal Changes in Biliary Duct Diameter with Correlated Bilirubin Levels in Confirmed Choledocholithiasis: A Prospective 3 Time-Point Observational Ultrasound Study. J Ultrasound Med. 2026. PMID: 42755155. doi:10.1002/jum.70487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。